QXL138AM

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

What's the purpose of the trial?

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

100

Last Updated

Participating Centers

There are 9 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

QXL138AM is a masked immunocytokine (MIC) that may help to kill certain types of cancer cells expressing the CD138 protein.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Part B1: QXL138AM Dose Expansion in Solid Tumors

Accepting patients

Part A1: QXL138AM Dose Escalation in Solid Tumors

Accepting patients

Part B2: QXL138AM Dose Expansion in Multiple Myeloma

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.